Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity
Company ‘Would Be Disappointed If It’s Not A Material Event In 2023’
Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.
You may also be interested in...
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
Cigna has responded to several questions from the insurer/payer side on the potential effect of multiple biosimilar Humira products launching in 2023 and beyond.
Teva has struck a further cash-and-medicines settlement agreement to resolve opioid-related claims in the US. A bench trial had been due to start in West Virginia by the end of this month, where Teva is to pay $75m over 15 years plus generic Narcan.